An investigational oral Janus kinase (JAK) inhibitor failed to meet most primary endpoints in a phase III trial of patients with moderate to severe Crohn's disease, but the failures might have ...

Oral JAK inhibitors offer patients with AD a ... Source Reference: Haag C, et al "A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema ...

The Janus kinase inhibitor baricitinib, in combination with narrowband ultraviolet B therapy, improved vitiligo, according to ...

Combining ultraviolet (UV) phototherapy with the Janus kinase (JAK) inhibitor baricitinib (Olumiant) helped patients with ...

JAK inhibitors have since emerged as a promising ... et al "Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic dermatitis: A population-based cohort ...

This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes ...

Discover a study that explores the effectiveness of JAK inhibitors to treat dermatological autoimmunity for people with Down ...

Additionally, the Janus kinase (JAK) family has emerged as another important target for therapeutic intervention. JAK inhibitors, such as ruxolitinib and upadacitinib, have been approved for ...

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

The FDA’s approval of the oral Janus kinase inhibitor Leqselvi was the ... Beneath the Surface: Addressing JAK inhibitor safety in alopecia with Brett King, MD, PhD Beneath the Surface is ...

If you’re under age 12, we don’t have any drug that is specifically indicated,” Dr. Lawrence F. Eichenfield said.